CASE Op-Ed, Washington Times: No ‘Magic Pill’ for Lowering Costs
Gerard Scimeca – Chairman, CASE April 5, 2019 – https://bit.ly/2IfnhvI In the ongoing public debate on the best way to effectuate...
CASE Signs Letter to Congress in Support of Hatch-Waxman Amendment to Protect Healthcare Innovation
April 3, 2019 Committee on Energy and Commerce 2125 Rayburn House Office Building Washington, DC 20515 Dear Chairman Pallone, On...
CASE Op-Ed, IJR: More Government Intervention Is a Dangerous Prescription for American Health Care
Gerard Scimeca – Chairman, CASE February 5, 2019 – https://bit.ly/2HTCLae Health care was the top issue when voters went to the polls in...
CASE Op-Ed, RealClear Health: New Cures Coming From Value-Based Outcome Medicine
February 1, 2019 Matthew Kandrch – President, CASE https://bit.ly/2GgtKFJ There is no question America’s healthcare system is too costly. We spend $3.3...
Government Plan on Drug Pricing Ads Won’t Help Consumers
Almost everyone agrees patients should know what their medicines cost them, and that drug pricing should be made more clear...
CASE OP-Ed – InsideSources: AARP Ads Against Drug Makers Driven by Self-Serving Profit Motive
Matthew Kandrach – President, CASE October 9, 2018 – https://bit.ly/2Oihkm5 Recent polling suggests that health care is still very much at the...
Pharmacy Benefit Managers: Raising Healthcare Costs with no Accountability
2018 has been a watershed year for the effort to reform our nation’s healthcare system and bring down the cost...
Pharmaceutical Importation: Too Dangerous To Allow
Last week, U.S. Department of Health and Human Services Secretary Alex Azar spoke at The Heritage Foundation about the importance...
Senator Durbin’s Proposal on Drug Advertisements: Simplistic and Wrong
Sen. Richard Durbin (D-IL) introduced an amendment to an appropriations bill this week that would force drug manufacturers to disclose...
Sec. Azar: Hospitals Pocket Billions from 340B Program at Expense of Consumers & Taxpayers, Program In Need of Reform
Last week, U.S. Health and Human Services (HHS) Secretary Alex Azar testified before Congress on the 340B program, an almost...
.@POTUS’ IRA is driving up Part D premiums for millions of Medicare beneficiaries, yet Dems like @SenSanders continue to help tout this disastrous legislation. The Biden-Harris @WhiteHouse is misleading the public on their policy’s real impact.
Two weeks from election day, the supposedly independent @FCC is proposing price regulation of #broadband by restricting what data plans companies can offer.
By prohibiting usage-based plans, the FCC would end up increasing prices FOR EVERYONE, including low-data users!
CASE Letter Urges FDA & FTC to Scrutinize Deal Between L’Oréal and Galderma -- "Both companies are currently under investigation or facing sizable lawsuits from claims that they have used harmful chemicals in their products."
https://caseforconsumers.org/2024/10/21/case-letter-urges-fda-ftc-to-scrutinize-deal-between-loreal-and-galderma/